Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986920 · ClinicalTrials.gov registry record · Phase 1
Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
A Phase 1 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01986920: Completed Phase 1 study, sponsored by Aclaris Therapeutics.
NCT01986920 is a Phase 1 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01986920, a Phase 1 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.
Primary Outcome
Mean Change in Score on the Physician Lesion Assessment Scale (PLA) of each Target Lesion. The PLAS is a four point scale from 0-3 with 0 being clear and 3 being the worst lesion. The primary effectiveness will consist of the mean change from Visit 2 to Visit 9 in PLA performed using Analysis of Covariance (ANCOVA) with Visit 2 PLAS as the covariate. Comparisons between vehicle and each active treatment group will be performed within the model using least-squares means and the common error term
Interventions
- DRUG A-101 25%
- DRUG A-101 32.5%
- DRUG A-101 40%
- DRUG A-101 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-10-22 |
| Est. Completion | 2014-02-25 |
| Phase | Phase 1 |
What the finished NCT01986920 record still lists
NCT01986920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 4 interventions - of which A-101 25% is the first listed.
NCT01986920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01986920 about?
NCT01986920 is a clinical study titled "Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis". Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.
What is the current status of trial NCT01986920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2013-10-22. Estimated completion is 2014-02-25.
What interventions are being tested in trial NCT01986920?
The interventions under investigation include: A-101 25% (DRUG), A-101 32.5% (DRUG), A-101 40% (DRUG), A-101 Vehicle (DRUG).
Who is sponsoring clinical trial NCT01986920?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01986920's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI